Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SWATI R SHAH

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1144424722
CMS profile
51581
Location
JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$8,855.68

238 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 238 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SWATI R SHAH

NPI 1144424722 · CMS profile ID 51581

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 238 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144424722?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SWATI R SHAH, NPI 1144424722, CMS profile ID 51581. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 238 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144424722?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SWATI R SHAH, NPI 1144424722, CMS profile ID 51581. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 238 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144424722?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SWATI R SHAH, NPI 1144424722, CMS profile ID 51581, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 238 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1144424722?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

238 matching records · $8,855.68 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 238 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 238.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $27.0007/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106067780 CMS
Amgen Inc. $5.8707/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116107689 CMS
Amgen Inc. $8.7407/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116107648 CMS
AstraZeneca Pharmaceuticals LP $32.8907/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105293069 CMS
GlaxoSmithKline, LLC. $6.5407/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116615824 CMS
PFIZER INC. $16.2707/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131490528 CMS
Ferring Pharmaceuticals Inc. $22.4707/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137509885 CMS
ABBVIE INC. $14.2507/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106067778 CMS
Alexion Pharmaceuticals, Inc. $24.7606/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1094022364 CMS
Amgen Inc. $6.2606/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116107682 CMS
Grifols USA, LLC $20.2906/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124741614 CMS
E.R. Squibb & Sons, L.L.C. $19.3406/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101427092 CMS
Amgen Inc. $25.5606/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116107642 CMS
Amgen Inc. $7.8606/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116107676 CMS
Lilly USA, LLC $24.8106/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135436511 CMS
Octapharma USA, Inc. $19.5306/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142318949 CMS
PFIZER INC. $2.2406/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131576452 CMS
Amgen Inc. $14.9106/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116107636 CMS
Novartis Pharmaceuticals Corporation $28.8306/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087262997 CMS
ABBVIE INC. $3.7006/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106067774 CMS
ABBVIE INC. $22.0206/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106067776 CMS
PFIZER INC. $25.2806/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131575419 CMS
GlaxoSmithKline, LLC. $16.2306/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116616800 CMS
ABBVIE INC. $8.2506/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106067772 CMS
ANI Pharmaceuticals, Inc. $28.6306/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091135623 CMS
Amgen Inc. $23.4906/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116107668 CMS
PFIZER INC. $15.9106/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131537343 CMS
Mallinckrodt Hospital Products Inc. $24.5105/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145135757 CMS
Amgen Inc. $14.2605/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116107588 CMS
E.R. Squibb & Sons, L.L.C. $23.5905/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101427084 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $84.1405/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117890259 CMS
ABBVIE INC. $16.6305/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106067770 CMS
Novartis Pharmaceuticals Corporation $5.7405/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087262989 CMS
Novartis Pharmaceuticals Corporation $20.9305/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087262991 CMS
Novartis Pharmaceuticals Corporation $9.2305/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087262993 CMS
Novartis Pharmaceuticals Corporation $8.1505/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087262995 CMS
PFIZER INC. $21.6905/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131454341 CMS
ABBVIE INC. $17.1205/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106067768 CMS
AstraZeneca Pharmaceuticals LP $19.7405/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105638730 CMS
UCB, Inc. $21.6405/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143043873 CMS
AstraZeneca Pharmaceuticals LP $18.0405/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104264033 CMS
UCB, Inc. $0.5405/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143043871 CMS
ABBVIE INC. $4.2505/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106067766 CMS
Lilly USA, LLC $28.0105/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135454235 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $25.5005/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117890255 CMS
Sandoz Inc. $16.7105/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089370978 CMS
ABBVIE INC. $21.8805/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106067764 CMS
PFIZER INC. $10.8805/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131541815 CMS
SANOFI-AVENTIS U.S. LLC $88.6005/06/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139799950 CMS
GENZYME CORPORATION $45.9005/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139799974 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,397.32 106
PY2020 $7,837.07 91
PY2021 $8,131.97 158
PY2022 $17,623.34 164
PY2023 $5,185.07 176
PY2024 $8,855.68 238
PY2025 $16,108.68 248

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $76,510.39 32
PY2024 Principal investigator $131,219.26 28
PY2023 Principal investigator $57,354.13 10
PY2022 Principal investigator $53,475.40 13
PY2021 Principal investigator $57,642.15 12
PY2020 Principal investigator $131,600.13 18
PY2019 Principal investigator $44,626.20 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $2,196.55 12/04/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202527242
Principal investigator 1 ABBVIE INC. $50.00 11/05/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202521787
Principal investigator 1 ABBVIE INC. $463.10 11/04/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202520305
Principal investigator 1 ABBVIE INC. $6,637.55 10/09/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202514823
Principal investigator 1 ABBVIE INC. $4,250.00 09/04/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202508896
Principal investigator 1 ABBVIE INC. $1,440.00 09/04/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202509036
Principal investigator 1 ABBVIE INC. $5,400.10 09/03/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202507545
Principal investigator 1 ABBVIE INC. $50.00 08/14/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202504789
Principal investigator 1 ABBVIE INC. $2,043.85 08/05/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202501780
Principal investigator 1 ABBVIE INC. $685.10 07/30/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202500462
Principal investigator 1 ABBVIE INC. $685.10 07/30/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202500464
Principal investigator 1 ABBVIE INC. $3,568.25 07/02/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202494667
Principal investigator 1 ABBVIE INC. $4,505.60 07/02/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202494791
Principal investigator 1 ABBVIE INC. $150.00 07/01/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202493769
Principal investigator 1 ABBVIE INC. $500.00 07/01/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202493771
Principal investigator 1 ABBVIE INC. $175.00 06/09/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202490659
Principal investigator 1 ABBVIE INC. $50.00 06/09/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202490661
Principal investigator 1 ABBVIE INC. $5,790.79 05/06/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202481391
Principal investigator 1 ABBVIE INC. $3,160.60 05/06/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202482213
Principal investigator 1 ABBVIE INC. $100.00 04/17/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202477618
Principal investigator 1 ABBVIE INC. $650.00 04/14/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202476264
Principal investigator 1 ABBVIE INC. $3,449.30 04/03/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202472648
Principal investigator 1 ABBVIE INC. $8,959.10 04/03/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202472670
Principal investigator 1 ABBVIE INC. $600.00 03/28/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202467135
Principal investigator 1 ABBVIE INC. $100.00 03/27/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202466742
Principal investigator 1 ABBVIE INC. $4,532.15 03/07/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202460870
Principal investigator 1 ABBVIE INC. $2,242.60 03/06/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202457875
Principal investigator 1 ABBVIE INC. $250.00 03/05/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202455811
Principal investigator 1 ABBVIE INC. $4,619.90 02/06/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202449549
Principal investigator 1 ABBVIE INC. $3,485.80 02/05/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202446010
Principal investigator 1 ABBVIE INC. $917.80 01/02/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202435886
Principal investigator 1 ABBVIE INC. $4,802.15 01/02/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202435959